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Abstract
Health research systems consist of diverse groups who have some role in health research, but the boundaries around 
such a system are not clear-cut. To explore what various stakeholders need we reviewed the literature including that on 
the history of English health R&D reforms, and we also applied some relevant conceptual frameworks.
We first describe the needs and capabilities of the main groups of stakeholders in health research systems, and explain 
key features of policymaking systems within which these stakeholders operate in the UK. The five groups are 
policymakers (and health care managers), health professionals, patients and the general public, industry, and 
researchers. As individuals and as organisations they have a range of needs from the health research system, but should 
also develop specific capabilities in order to contribute effectively to the system and benefit from it.
Second, we discuss key phases of reform in the development of the English health research system over four decades - 
especially that of the English Department of Health's R&D system - and identify how far legitimate demands of key 
stakeholder interests were addressed.
Third, in drawing lessons we highlight points emerging from contemporary reports, but also attempt to identify issues 
through application of relevant conceptual frameworks. The main lessons are: the importance of comprehensively 
addressing the diverse needs of various interacting institutions and stakeholders; the desirability of developing 
facilitating mechanisms at interfaces between the health research system and its various stakeholders; and the 
importance of additional money in being able to expand the scope of the health research system whilst maintaining 
support for basic science.
We conclude that the latest health R&D strategy in England builds on recent progress and tackles acknowledged 
weaknesses. The strategy goes a considerable way to identifying and more effectively meeting the needs of key groups 
such as medical academics, patients and industry, and has been remarkably successful in increasing the funding for 
health research. There are still areas that might benefit from further recognition and resourcing, but the lessons 
identified, and progress made by the reforms are relevant for the design and coordination of national health research 
systems beyond England.
Introduction
While there is a long history of scientists and physicians
conducting health or medical research, a health research
system is a newer concept. A national health research sys-
tem has been defined as 'the people, institutions, and
activities whose primary purpose is to generate high
quality knowledge that can be used to promote, restore,
and or maintain the health status of populations. It can
include the mechanisms adopted to encourage the utili-
zation of research' [1]. This definition encompasses a
wide range of actors and approaches from the public and
private sectors, academia, charitable foundations, and
civil society who all have some stake and interest in
health research and its utilisation.
In practice, it is difficult to draw boundaries around
such research systems and the task is made more compli-
cated by changes in the ways in which knowledge is gen-
erated by scientific research. The classic and 'internalist'
model of scientific research - termed Mode 1 - posits that
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science has its own structures and processes, and there-
fore should determine its own priorities [2,3]. This con-
cept has long been debated, and is increasingly
challenged by the growing acceptance of the argument
that science, state, and society do, and should, interact
with, and influence, each other [4-7]. A complex range of
stakeholders influence how research is defined, con-
ducted and used. The term Mode 2 research is used to
reflect research that is conducted specifically with a view
to being applied on behalf of society, the state and the
economy [3], and, in this sense, encompasses both
research and development (R&D). Because we are taking
this broad perspective, we use the terms 'research' and
' R &D'  in t e r c hang ea bl y in t his  pa pe r .  Ot he rs  also  ar gue
that science is practised in a diffuse and unbounded
social context - an 'agora'  [7] - that is an open market
place or network, 'with many different actors, political
and economic interests and competing scientific knowl-
edge claims' [8]. Reflecting this complexity in the nature
of research, there is often also a range of health research
systems within any country that seek to achieve specific
objectives. Considering national health research systems,
there is general agreement that one of the main objectives
should be to ensure that these diverse actors and health
research systems collaborate and that the system is man-
aged in a way that promotes both good science and the
public good [1,9].
Following this Introduction, the paper has three main
sections:
1. First, we describe the needs that key stakeholders in
any health research system are likely to have.
2. Second, we focus on how the research system funded
by the English Department of Health over the last four
decades attempted to meet the needs of various stake-
holders.
3. Third, we analyse, from both stakeholder and histori-
cal perspectives, how a more coherent national health
research system is gradually emerging in England, and we
attempt to draw some lessons about best way to build a
health research system to meet the needs of diverse
stakeholders.
To conduct this analysis, we reviewed the overlapping
literature on stakeholder needs and that on the history of
health research reforms in England. The long history of
developments related to publicly funded health research
in England is comprehensively addressed by Shergold and
Grant [10]. Our paper draws on this and other detailed
accounts of specific phases and developments of the R&D
system of the English Department of Health (DH) [11-
15]. Key phases of reform in this system have concen-
trated on the needs of different stakeholders to varying
degrees. In particular, we draw extensively on the seminal
analysis by Maurice Kogan and Mary Henkel of the
reforms in the 1970s to the research system of the English
DH, the full title of which at that time was the Depart-
ment of Health and Social Security. First published in
1983, this analysis emphasised the 'multi-modal' nature of
stakeholders' roles and interactions, and the importance
of 'interface mechanisms' between stakeholders and the
health research system [11]. This line of analysis was fur-
ther developed by Hanney et al, in the context of a World
Health Organization coordinated international exercise
to analyse national health research systems [16]. The
'Interfaces and receptor model' that was developed high-
lights health research system interfaces and the related
tasks of research specification, commissioning, conduct,
synthesis and appraisal, dissemination, application, and
feedback. In the English system this range of tasks was
explicitly recognised in the reforms of the early 1990s,
which covered both research and development [17]. In
drawing lessons from each phase of reform, we highlight
points that emerged from contemporary reports and also
use the above frameworks to identify and analyse issues.
While this analysis is situated in the English health
R&D system, and specifically in the part of the system
covered by the government's health department and the
health care system, the issues discussed are relevant for
the design and coordination of national health research
systems far more widely, and might have some applicabil-
ity to large systems within national systems, for example
the US Department of Veterans Affairs. Therefore, we
provide generic definitions of specifically English organi-
sational arrangements, and also aim to draw lessons from
the reforms to the English health R&D system that could
also have more general applicability elsewhere. This is
especially so because there is a general trend in many
countries towards the involvement of more stakeholders
in research systems, and hence the need for greater coor-
dination across any such system [18,19].
Stakeholders in Health Research Systems
At the core of any health research system are the
researchers who undertake the research, the diverse bod-
ies that fund it, and those organisations that host it. Then
there are a range of other interests that relate to health
research in various ways. In a stakeholder analysis it is
useful to focus on the key groups who are seen as the
recipients of the research and identify what they are likely
to need from the health research system. There have been
successive reforms of that part of the national health
R&D system that is funded by the English DH over the
last four decades. To varying degrees, each of these suc-
cessive phases has given particular attention to the needs
of specific stakeholder groups:
• policymakers (and managers),
• professionals in the health-care system,
• patients and the wider public, and
• industry.Hanney et al. Health Research Policy and Systems 2010, 8:11
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The stakeholders are shown at the four corners of Fig-
ure 1 which summarises their needs. All the groups inter-
act with and influence each other, but consistently the
fifth stakeholder group, the researchers, who are at the
centre of F igure 1, feel the pressure from many of the
other stakeholders. The needs of these five key stake-
holder groups are described in detail below, but first we
describe the context in which they operate within the
English system.
Context in which key stakeholders operate within the 
English system
In recent years the Treasury (which is the UK equivalent
to departments or ministries of finance in other coun-
tries) has become increasingly interested in performance
and outputs when making the overall decisions about lev-
els of public expenditure and allocations to the various
government departments (the term by which ministries
are known in the UK). Such departments include several
that receive money to fund health research. Whilst the
health department has remained a constant player over
many years, and funds research directly through its own
R&D Division and through the National Health Service
(NHS), the other departments involved in funding health
research have varied. Most universities in the UK receive
considerable public funding but they are charter institu-
tions. This means they are not strictly public sector
organisations: 'their status has been that of almost wholly
independent institutions but deferring to public policies
which largely constitute the conditions under which the
bulk of their resources have been secured' [20]. The uni-
versities are funded for both teaching and research
through funding councils that at various times during the
last four decades have reported to either the main educa-
tion department, or to a separate department, or to a sec-
tion of a department dealing with business. In addition,
the research councils in England provide a separate but
major source of public funding for research: in the health
field the Medical Research Council (MRC) was created in
the early 20th Century [10]. Like the universities, the
research councils have traditionally enjoyed a consider-
able degree of autonomy [20]. The government depart-
ment to which the research councils report has changed
frequently and has included: Education; Industry; Busi-
ness; and the Cabinet Office, which is the central co-ordi-
nating department in British government.
The role of the private and charitable sectors in health
research is increasingly and explicitly recognised. In
terms of expenditure it was estimated in 2005 that the
annual private sector, ie industry, medical research fund-
ing was about £5,000 million in the UK, compared with
£1,700 million from public sources and £650 million from
the medical research charities [21].
In terms of the locations where the research is con-
ducted, there is recognition in recent reforms that health
researchers work at multiple organisational levels in the
publicly-funded health R&D system, each with different
stakeholder considerations, including in universities and
in hospitals (and often in the medical schools that com-
bine the two), and in units funded by the main research
council in this field, the MRC. Furthermore, there is an
extremely large sector of health R&D conducted in the
laboratories of industrial companies. Most of the charita-
ble and some of industry's funding for science goes to
research conducted in public sector institutions.
There is considerable interest in science policy in the
legislature. However, there is a long history in the UK, as
expressed in the Haldane Report [22], of the government
delegating autonomy to the research councils over which
projects they should fund, and also of legislation govern-
ing research being relatively limited. Of the two chambers
in the UK Parliament it is possibly the unelected and gen-
erally less powerful chamber, the House of Lords, that has
had the most influence over the way science policy devel-
ops. This is partly because of the role of its Science and
Technology Select Committee, which consists of some of
the most senior scientists in the country, often appointed
to the House of Lords because of their scientific achieve-
ments [12].
There is increasing public interest in medical research
and many people obtain science and health information
mainly from the mass media [23,24]. There is also grow-
ing evidence that the mass media can influence health
policy agendas, the utilisation of health research, and
health behaviours [25]. It is increasingly seen as desirable
for the health R&D system to devote some resources to
attempting to enhance the health literacy of both the gen-
eral public and parts of the mass media.
There are further complications. Some individuals play
more than one role, and are therefore members of more
than one stakeholder group. For example, many medical
academics are both practitioners and researchers. The
various stakeholders relate to each other, and with health
R&D, in various settings, including ones related to gov-
ernmental, managerial and clinical policy making. Fur-
thermore, each group can also be 'multi-modal', meaning
that there can be great variations between, for example,
policymakers from different parts of the Department of
Health (DH) or between the skills and attitudes of scien-
tists working in different branches of health research [12].
Whilst health professionals can be referred to as one
stakeholder group, in practice, there can be great differ-
ences between those filling the various roles, and such
differences can be reflected in how they relate to research
[26].Hanney et al. Health Research Policy and Systems 2010, 8:11
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Figure 1 Examples of needs in relation to publicly funded health R&D.
 research to inform and confirm clinical 
practice (including safety) and service 
organisation
HEALTH PROFESSIONALS’ NEEDS
 access to training and continuing 
education informed by research
 resources for research implementation
Capacities to:
 critically appraise, evaluate and absorb 
research
   identify areas where further research is 
required and set agendas
   (in some cases) conduct research useful 
to the healthcare system.
 access to health research, and ongoing 
communication on health risks and 
resources, so as to make informed 
decisions about behaviour and health 
services
PATIENTS’/ PUBLIC’S NEEDS
 mechanisms to engage with policy, 
service, and research processes 
 accountability of health research, 
policy, and service provision
Capacities to
 access and understand research 
evidence (ie health literacy)
Research liaison and brokerage tasks/ Interface and boundary mechanisms
 resources for research and its dissemination
RESEARCHERS’ NEEDS
 control/ independence  in research process
 acceptance of range of research methods and   epistemologies
 appropriate incentives and assessment for different types of research
Capacities to: 
 conduct high-quality research
 communicate research
Research liaison and brokerage tasks/ Interface and boundary mechanisms
 research to provide wider range of 
validated concepts, experiences and 
technical knowledge (including on 
safety) than otherwise available
POLICYMAKERS’ & HEALTH 
MANAGERS’ NEEDS
Capacities to:
 scrutinise areas of policy to identify 
knowledge gaps or conflicts
 determine if research is required to 
address these problems
 define research needs in outline to 
enable resource allocation and 
researcher selection 
 evaluate and assimilate research 
findings into policy
 promote research dissemination  
 a flow of findings from publicly 
funded research
INDUSTRY’S NEEDS
 interaction with the public health 
research system over agendas etc
 a health care system and health 
research system capable and willing 
to host and conduct trials of new 
products
Capacities to:
 liaise with other stakeholdersHanney et al. Health Research Policy and Systems 2010, 8:11
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Deciding where to draw the boundary for an analysis of
any part of the health research system is never clear-cut,
and where possible the analysis should consider the gov-
ernance structures for the funding and management of
health research, and discuss some of the challenges faced.
In this analysis we primarily focus on the health R&D
conducted in public organisations (counting universities
as 'public organisations') and funded through the English
Department of Health and the health care system it pro-
vides (ie the NHS). But we also consider the wider range
of stakeholders that influence, and draw on, that research
system. Our analysis, however, goes further. We describe
the developments in the English DH's system of research
funding since the 1970s that have now led to the creation
of a national health R&D system that seeks both increas-
ing coordination across the whole publicly funded sys-
tem, and improved liaison with industry and with the
medical research charities.
The five key stakeholder groups on which this analysis
focuses are presented below.
Policymakers and managers in the health care system
For the purposes of our analysis, NHS managers are clas-
sified alongside policymakers, as depicted at the left-hand
lower corner of Figure 1. This is based on the interlinked
nature of their needs from health research systems. The
u n d e r l y i n g  a s s u m p t i o n  i s  t h a t  p o l i c i e s  a n d  m a n a g e r i a l
practices which are research-informed will be better than
otherwise would have been the case [12,16]; research
exposes policymaking to a wider range of validated con-
cepts and experiences than those that might otherwise be
available in time-limited and politically constrained pro-
cesses of policy deliberation. Research legitimises some
policies and throws legitimate doubts on others.
Different types of research are likely to be required to
inform different types of policies in health care. These
include, for example, 'legislative, administrative, or clini-
cal' policies [27]. The utilisation of research in policymak-
ing can be conceptualised in a range of ways [28] and a
three-fold categorisation is sometimes adopted: instru-
mental, conceptual or symbolic [29,30]. Instrumental use
involves research findings being directly used in policy
formulation. Conceptual use refers to a type of enlighten-
ment mode of utilisation in which the ideas from research
gradually seep into the way in which issues are thought
about. Finally, symbolic use of research occurs when it is
used to support a position already taken, which may be to
continue with existing policies.
In terms of clinical policies, the technical issues around
the effectiveness and cost-effectiveness of clinical inter-
ventions are key considerations. It is often thought that
research has more impact, at least in a more readily iden-
tifiable instrumental way, on clinical policies than it does
on legislation - although there is now increasing evidence
of instrumental impact with regard to the latter [31]. It
also is likely that there is longer-term conceptual impact
on the way in which legislative and administrative poli-
cies are viewed, but it can be difficult to link this to spe-
cific research.
The experience of Kogan and Henkel, and the message
of many subsequent analyses, is that policymakers need
to develop various capabilities in order to gain the bene-
fits from research [12,32,33]. These include capabilities
to: scrutinise areas of policy to identify knowledge gaps
or conflicts; determine if research is required to address
these problems; and define research needs in outline to
enable resource allocation and researcher selection.
These activities often take place at the project specifica-
tion and commissioning interface between research and
policy where it is claimed that a collaborative approach
between policymakers and researchers is likely to pro-
ductive [4].
Long-term relationships developed between research-
ers and potential users in the health care system are seen
as a productive way of developing collaborative
approaches, but as Kogan and Henkel showed there can
be many obstacles to doing this consistently [11], includ-
ing the frequent turn-over of staff in policymaking roles.
Increasingly researchers and policymakers in the UK, as
elsewhere, are developing networks that contribute to
research agenda development [31].
Just like policymakers, health service managers and cli-
nicians, including those who make decisions at local lev-
els, are likely to benefit if they have the capacity to help
identify what they need from research through scrutinis-
ing areas of service organization or provision and defin-
ing suitable topics. For those working at local levels,
however, there have traditionally been fewer opportuni-
ties to be involved in the commissioning process for
research to meet the needs of their specific organisations
or services, although this is now beginning to change.
Once the research has been produced, policymaking
and managerial systems also need the capabilities to eval-
uate these findings and assimilate them into national and
local policy. Various mechanisms and capabilities can
help to promote research dissemination and implementa-
tion [12,16]. These include: developing appropriate bro-
kerage roles to assist the transmission of the findings
from the researchers to the relevant policymakers; ensur-
ing that the bodies that receive and use the research find-
ings, (i.e. the 'receptor bodies') have the requisite
organisational capacity to absorb the findings; and the
provision of relevant training for policymakers, adminis-
trators and managers [12,16]. How far all these capabili-
ties are the responsibility of the health research system to
provide is debatable, but one area in which health
research systems have increasingly been attempting to
meet the needs of policymakers and managers is throughHanney et al. Health Research Policy and Systems 2010, 8:11
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the development of capacity to undertake systematic
reviews, and interpret the results from them. A recent
international review of health research funding agencies'
support and promotion of Knowledge Translation found,
however, considerable variation in their level of engage-
ment in such processes [34].
In some health care systems there have recently been
more assertive attempts to generate policies to influence
the behaviour of health care professionals when conduct-
ing their clinical activities. For example, in England, the
Department of Health established a series of ad hoc com-
mittees to draw up National Service Frameworks that
included recommendations for the organisation of health
care in a specific field, such as diabetes, or for a specific
group, such as older people. The DH also created the
National Screening Committee (NSC) that generates pol-
icies about what types of screening will be provided
within the NHS, and the National Institute for Health and
Clinical Excellence (NICE) that issues policies in the form
of guidance about whether specific treatments should be
funded. Clinicians and commissioning bodies in the
Health Service are increasingly obliged to follow such
guidance. NICE also issues guidelines which provide rec-
ommendations for clinical behaviour in broader areas of
health care. Some of the organisations that generate such
policies, including NICE in England, can be described as
receptor bodies for research [12,16]. International evi-
dence suggests that Health Technology Assessments will
not necessarily be much used unless a policymaking, or
receptor, body is properly established to use the research
[16].
There is a complex interplay between developing the
capacity of people working in existing policymaking, or
receptor, bodies to receive and use research findings, and
going further and specifically creating new receptor
structures to undertake evidence-based policymaking. In
terms of providing training to develop capacities, the
Canadian Health Services Research Foundation runs the
Executive Training for Research Application programme
designed to, 'improve the receptor capacity of both health
service executives and the organizations in which they
work' [35].
Professionals in the health care system
Professionals working in the health care system need
research to inform and confirm clinical practice, includ-
ing research on the safety, effectiveness and cost-effec-
tiveness of therapies. Similarly, professionals who also
have responsibility for service organisation benefit from
research findings to inform their decisions. Health care
systems and organisations are immensely complex and
there are many ways in which professionals, at an individ-
ual level or as part of clinical teams, can access, or be
exposed to, research findings. These include through
journals, online resources, conferences and through
receiving training and continuing education that is
informed by research. There has been extensive interna-
tional debate about how professionals should be encour-
aged to access to research findings, and be informed by
them [36].
There is an increasing realisation that not only do indi-
viduals need good access to research but also that work is
needed at the level of the health care organisation and the
system to encourage the implementation of health
research [37,38]. In addition to the behaviour of individu-
als and teams, and the cultural changes that can occur at
organisational and structural levels, there are also, as
noted above, increasing attempts within some health care
systems to influence clinician behaviour through policies
made at a national level, which include clinical guidelines
produced by professional bodies. Professionals who want
to implement research findings also need the resources to
do so, and capacities such as the ability to critically
appraise, evaluate and absorb research. Training profes-
sionals to acquire these capacities has, at times, been seen
as the responsibility of the health research system, for
example, by running critical appraisal courses [39].
Turning to the production of research, there are several
roles professionals can play. First, it is likely that profes-
sionals will be most responsive to research if they believe
it is relevant to their needs. This is more likely to be the
case if they have been able to exploit opportunities to
help identify areas where further research is required,
and thus to help set agendas. Second, and more obviously,
the medical academics and other health professionals
who engage in research need capacities and opportunities
to conduct such research, as is discussed below in the
sub-section on the needs of researchers.
One of the benefits of funding research widely in a
health care system, so that many of the professionals have
some experience of being involved in research, is that it is
thought to increase the capacity of people working in that
system to take on board and utilise research findings in
general. This concept of increasing the capacity of the
health care system to absorb research (called the absorp-
tive capacity) through conducting research has long been
built into ways of assessing the impact of health research
[40].
Patients and the general public
Increasingly patients and the general public wish to have
access to research evidence so as to make informed deci-
sions about their own care and behaviour in relation to
health services, and to have greater understanding of
health risks [5,41]. Indeed, the constitution of the World
Health Organization states: 'An informed opinion andHanney et al. Health Research Policy and Systems 2010, 8:11
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active cooperation on the part of the public are of the
utmost importance in the improvement of the health of
the people.' [42].
But to be able to gain these benefits, patients and the
public need to have various capacities, including health
(and perhaps health research) literacy, so as to be able to
access and understand research evidence [43]. As noted, a
systematic review found that the media are leading
sources of health information targeted by those aiming to
influence behaviour of the public (as well as of health pro-
fessionals) [25]. This increases the importance of health
research systems exploring the best ways to engage the
mass media, and to consider the most appropriate forms
of health research communication. This is important not
only to ensure the widest possible coverage for evidence-
based health research findings, but also to counter the
dangers of misinformation, for example from inadequate
research.
Patients and members of the public, and their represen-
tatives, either wish, or at least are increasingly being
encouraged, to engage with research processes such as
agenda setting and commissioning [44,45]. These moves
partly reflect broader socio-political changes, in this case
for more participatory forms of decision-making [5], but,
especially when it was first being undertaken, there was
often confusion about what patient involvement entailed
[46]. A systematic review on consumer involvement in
health research agenda-setting published in 2004 claimed
ongoing collaboration had the greater impact compared
with one-off consultation, but concluded that, 'what we
know about the advantages and disadvantages of meth-
ods of involving consumers in agenda setting rests on
weak short-term evidence and almost entirely speculative
long-term evidence' [47]. Furthermore, even by 2009 the
latest review refers to gaps in the evidence about the
impact of public involvement on research funding and
commissioning [45].
To be able to participate fully patients need to develop
appropriate capacities, and several health research sys-
t e m s  h a v e  e x p l o r e d  w a y s  t o  p r o v i d e  t r a i n i n g  [ 4 8 ]  a n d
develop innovative techniques [49]. Furthermore,
attempts to increase the involvement of members of the
public also require flexibility in the approach adopted by
the members of research commissioning panels from tra-
ditional scientific backgrounds. There is an important
need for trust and respect on both sides, and it is recom-
mended that new protocols are adopted in such circum-
stances [50].
As with all groups of stakeholders, patients do not act
as a homogenous group. For example, organised patient
groups tend to push for more research in their particular
field, and the lack of a strong advocacy group for public
health research may have contributed to the traditionally
low levels of funding in that area.
Industry
The pharmaceutical and medical device industries also
need a flow of findings from publicly funded research, in
terms of new knowledge, research material and tech-
niques including assays, epidemiological data, etc. In the
commercial world in general, a considerable proportion
of the investment made by industry in its own laborato-
ries is to ensure sufficient absorptive capacity; i.e. the
ability to assimilate and exploit external knowledge [51].
In order to ensure this exchange of knowledge occurs
more systematically, industry works with researchers to
develop mechanisms such as Material Transfer Agree-
ments which govern the transfer of tangible research
materials between two organisations, such as industry
and a part of the health research system, when the recipi-
ent intends to use it for his or her own research purposes.
In order to maximise the benefits from publicly funded
research, industry is increasingly active in seeking to
influence the agenda of the publicly-funded health
research system at an organisational level, and to develop
links with individual researchers and research groups.
Industry is also interested in mechanisms whereby they
can interact with the other stakeholders of health
research systems.
Furthermore, industry needs a health care system and
health research system capable and willing to host and
conduct trials of new products, and here high income
countries are facing an increasing challenge from low and
middle income countries. Most countries have some type
of drug regulatory agency that decides which products to
approve for use in their country, or for use in their pub-
licly-funded health care system. Industry often takes con-
siderable steps to influence the health research system
mechanisms put in place to provide data for the drug reg-
ulatory agency.
There are inevitably concerns among the other stake-
holders about the influence of the private sector given
that roles and interests of the public and private sectors
are not always congruent or clear. For example, a system-
atic review found that trials funded by the pharmaceuti-
cal industry tended to have outcomes that favoured
products made by the sponsoring companies [52]. Fur-
thermore, there are particular concerns about the part
played by the tobacco industry in trying to undermine
independent research on the health dangers of smoking
[53].
Researchers
It is in everyone's interests that the central stakeholders,
i.e. the researchers themselves, are adequately supported
by others in any health research system. Nevertheless,
there have been occasions when the money allocated for
research within health care systems has been vulnerable
to being siphoned off to be used by other parts of a hard-Hanney et al. Health Research Policy and Systems 2010, 8:11
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pressed health care system. For researchers, a key consid-
eration during periods of reform to the health research
system is what will happen to the level of resources avail-
able for their research.
Researchers also need broad acceptance for the range
of research methods they might use and the accompany-
ing epistemologies. Here there can be problems, particu-
larly as the scope of health research has widened and
attempts are made to introduce a wider range of qualita-
tive methods [54].
All researchers also need appropriate incentives. A
more complex issue is that researchers need to feel that
the assessment of their research reflects the basis on
which it was commissioned. In particular, health services
researchers have long felt that the criteria used to assess
policy-relevant research have not always been appropri-
ate [12,31]. Amongst analysts of research systems there is
a wider recognition that if researchers are now operating
in an agora - an open market place of ideas - then the cri-
teria on which they are assessed should reflect this [8].
However, in practice, the needs of applied researchers
have often not been taken into account when academic
assessment systems were devised, either by government
or by the universities themselves.
Linked to the above points, but often potentially in con-
flict with the needs of other stakeholders, is the need that
most researchers feel for a reasonable level of control
over the methods used - at least during the research pro-
cess itself. It has traditionally been claimed, especially in
the Mode 1 model of research (i.e. the classic or internal-
ist model often found in basic research), that the most
good will come to society when researchers are left free to
determine their own research agendas and priorities,
driven by the imperatives that come from the unfinished
business in the science [2]. But, as noted in the introduc-
tion, this is now a matter of contention. In contrast to
those who fear losing control of the research agenda,
some applied researchers increasingly claim that a collab-
o r a t i v e  a p p r o a c h  i s  l i k e l y  t o  b e  m o r e  p r o d u c t i v e  t h a n
researchers either devising their own agendas or simply
being invited to do specific research to meet the needs of
policy 'customers' [4]. They claim that a collaborative
approach will result in research for which there will be
potential users [4], but the approach requires appropriate
structures to be created. Within this, there must be scope
for the researchers to influence the agenda, particularly in
relation to defining researchable topics, and have consid-
erable autonomy over the methods to use. There is
mounting evidence that some programmes are able to
adopt a successful collaborative approach [55].
Researchers need various capabilities. These include
the capacity to conduct high-quality research and, it is
increasingly argued, to communicate research findings
and collaborate with policymakers. For these capabilities,
more so than those of any other stakeholders, the health
research system has a responsibility to meet the need.
Key Phases of English health R&D Reform
This next section of the analysis provides an overview of
the four main attempts to reform aspects of the English
health research system, and discusses how these reforms
addressed the stakeholder needs identified in the preced-
ing section. Whilst the needs of all stakeholders featured
to some degree throughout, each phase in the Depart -
ment of Health's R&D reforms in England over the last
four decades can be viewed, and were presented at the
time, as emphasising the needs of different stakeholders:
1. 'Government as consumer of research' - The Roth-
schild reforms in the 1970s focused on strengthening
links between government and science, and devel-
oped clear 'customer-contractor' relationships
between policy officials and researchers for applied
research [56].
2. 'The National Health Service (NHS) as consumer of
research' - The NHS R&D/Peckham reforms from the
early 1990s were directed towards integrating
research and development into the NHS through try-
ing to improve the links with its policymakers, man-
agers and professionals - to improve health and health
care, and led to the establishment of the NHS R&D
programme [57].
3.  'Multiple stakeholders including patients as con-
sumers of research' - The health department's R&D
strategy proposed in 2005, Best Research for Best
Health [21], built on the previous phases and addi-
tionally positioned patients as the ultimate consumers
of health research, leading to the establishment of the
National Institute for Health Research (NIHR) [9].
4. Including industry and other interests in a compre-
hensive overview of English health R&D. The Cooksey
Review was initiated by the Treasury almost immedi-
ately after implementation of the Best Research for
Best Health reforms had begun [58]. The review
examined the whole publicly funded system of health
R&D in the UK, including the activities of the DH/
NHS R&D programme and of the MRC where the tra-
ditional view of the independence of researchers is
strongest. The review aimed to consider the needs of
all customers, including some groups such as industry
that hitherto had been less well represented.
Table 1 presents a timeline of key events in this history.
The main element of each of the four phases listed above
is shown in bold with the subsequent events constituting
the main developments during that phase, or the key
developments that drove the subsequent phase. For the
final two phases, however, the main events run concur-
rently because the establishment of the NIHR was fol-Hanney et al. Health Research Policy and Systems 2010, 8:11
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Table 1: Timeline of four phases of reform and main 
developments in English health research system since 
1970
Date Title or name of key document or reform
1971 Rothschild Report: The Organisation and 
Management of Government R&D: 
Led to government departments such as the 
health department receiving some of the funds 
of research councils and becoming the 
customers for research conducted by their 
contractors.
1973 Concordat signed transferring some Medical 
Research Council funds to the English 
Department of Health's research division. 
Consultative committee structure created for 
policymakers and researchers.
1978 Rothschild reforms such as consultative 
committees began to be dismantled.
1988 House of Lords Select Committee on Science and 
Technology: Priorities in Medical Research.
1991 NHS R&D Programme: launched by Michael 
Peckham, first health department Director of 
R&D:
R&D programme established to meet the needs 
of NHS.
1992 UK Cochrane Centre established as part of the 
NHS R&D Programme's information systems' 
strategy. This inspired the international 
Cochrane Collaboration.
1993 NHS Health Technology Assessment programme 
established.
1994 Culyer Report made recommendations to 
increase the accountability and transparency of 
research funding in the NHS and to protect the 
major research and teaching hospitals
1999 NHS National Institute for Clinical Excellence 
(NICE) established.
2002 Clinical Academic Medicine in Jeopardy Report 
published by the Academy of Medical Sciences 
to highlight the fears that academic medicine 
was becoming seen as a less attractive career
2004 UK Clinical Research Collaboration (UKCRC) 
created by the English Department of Health and 
many other stakeholders to enhance clinical 
research
2004 Final report from Research for Patient Benefit 
Working Party endorsed the creation of the 
UKCRC as a key part of developing a clinical 
research infrastructure embedded in the NHS,
2005 'Best Research for Best Health' consultative 
document led to a series of reforms introduced 
between 2006-9:
Comprehensive set of proposals aimed at 
meeting the needs of patients and other 
stakeholders
2006 Best Research for Best Health strategy document 
outlined the reforms to be introduced following 
the consultation to create the National Institute 
for Health Research (NIHR). Key features 
included:: building on the developing clinical 
research networks, raising the status of clinical 
researchers, introducing new funding 
programmes and centres to complement 
existing programmes such HTA programme.
2007 The first (of now 12) Biomedical Research Centres 
announced to support a critical mass of leading 
researchers in NHS/university partnerships that 
are driving innovation
2008 First 100 members of new NIHR College of Senior 
Investigators appointed thus raising status of 
clinical researchers and academic medicine
2009 NIHR Progress Report described how the Best 
Research for Best Health strategy is being 
comprehensively delivered by working across 
the NHS and with patients, health research 
academic institutions and industry.
2006 Cooksey Review: 
Review of all publicly funded health research: 
endorsed Best Research for Best Health reforms, 
emphasised industry's needs and the importance 
of translational research, recommended creation 
of Office of Strategic Coordination of Health 
Research (OSCHR).
2007 OSCHR established as recommended. It 
integrated public expenditure bids from the 
English Department of Health (for the NIHR) and 
the business department (for the MRC) and, 
based on their success, achieved a record 
funding increase for health research. A 
Translational Medicine Board set up to work with 
MRC and NIHR to develop a fully aligned 
approach in translational research.
Table 1: Timeline of four phases of reform and main 
developments in English health research system since 
1970 (Continued)Hanney et al. Health Research Policy and Systems 2010, 8:11
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lowed so rapidly by the Cooksey Review, which covered a
broader spectrum of research.
The Rothschild reforms: government as consumer of 
research
In the 1970s, a major phase of R&D reform in England
followed the 1971 Rothschild Report [56]. Health
research system reforms in this phase were designed, in
particular, to produce knowledge that would help policy-
makers in central government departments, including
those responsible for health and social services policy.
The Rothschild reforms envisaged government as the
'customer' for research, and the scientific community as
the 'contractors', and described the relationship as being,
'the customer says what he wants, the contractor does it, if
he can, and the customer pays'. [56]. Many leading bio-
medical researchers opposed the resultant transfer of
some research funds from the Medical Research Council
to the health department which occurred through a con-
cordat signed in 1973. Further, the use of the terms 'con-
tractor' and 'customer' in relation to research was
contentious at the time (and has continued to be so for
some commentators [59]). Critics of the Rothschild prin-
ciple have long claimed that it threatens the indepen-
dence of researchers because it means the customer can
determine the nature of the work to be undertaken in
Government-funded research. Critics also dislike the
deliberate incorporation of language from industry and
commerce into academic research.
The English health department, which, as noted earlier,
was then called the Department of Health and Social
Security (DHSS), commissioned a seven-year formative
evaluation of the reforms. This evaluation showed the
difficulties in getting two very different systems - science
and government - to work together. In their analysis,
Kogan and Henkel highlighted the diversity of impera-
tives, tasks, approaches, and roles within and between
each system [11,12]. Government rarely found it possible
routinely to devote the time and resources to being an
informed customer. Furthermore, for institutional and
epistemological reasons, scientists often struggled to pro-
duce the knowledge needed by policymakers and, in turn,
policymakers faced difficulties in acting as 'receptors'
who could receive and use that knowledge. For much of
the research commissioned, the Department was not
even acting as the primary customer, but, rather, was in
the position of a secondary or proxy customer for the
field authorities and practitioners of the NHS who might
have benefitted from research commissioned by the
Department. This highlights the difficulties involved in
attempting to identify, let alone meet, the needs of all
stakeholders.
Kogan and Henkel identified that mechanisms at the
boundaries - later called interfaces - between the research
and policy systems, needed to be further developed in
order to enable scientists and policymakers to work col-
laboratively, whilst taking into account their differences
[11,12]. Such mechanisms included the Research Liaison
Groups established in the 1970s, which attempted to
bring together researchers, policymakers, professionals
and research managers to identify relevant research top-
ics in selected research areas. These mechanisms were of
variable success, but some continued working well many
years after other elements of the Rothschild reforms had
been dismantled [11,12]. In addition to the variable suc-
cess of those Research Liaison Groups that were created,
there were quite a few topics which did not have their
own group. In addition, and through its Policy Research
Programme, the Department also had 'core'-funded
Research Units (on rolling five-year contracts) and long-
term programmes, some predating the Rothschild
reforms. They, and similar units later funded by Regional
NHS R&D Programmes, played an important role includ-
ing developing collaborative research agendas [60-62].
Research Liaison Officers, who were recruited by the
Department during this period (and are still a key part of
the DH's research management today), helped such
agenda building by acting as a 'hinge' between the people
in the Department who took the lead on making policy
a n d  t h e  h e a l t h  r e s e a r c h  c o m m u n i t y .  I n  d o i n g  s o  t h e y
were fulfilling part of the 'brokerage role ' identified by
Kogan and Henkel as being a key mechanism [11]. The
N u rs ing  Resea r c h U nit  a t K ing 's  C oll ege ,  U ni ve rs it y of
London, is an example of a unit from that time that
r e c e i v e d  c o r e ,  o r  l o n g - t e r m  r o l l i n g ,  f u n d i n g .  I t  i s  s t i l l
thriving and, at the time of its recent change of name to
become the National Nursing Research Unit, policymak-
ers continued to be able to describe its importance to
them [63]. Its Research Liaison Officer continues to play
an important brokerage role in linking the unit with the
relevant parts of the Department.
The programme of reviews of the Policy Research Pro-
gramme core-funded units conducted from 1979 also
highlighted some of the difficulties that could be faced by
scientists working on policy-related topics. When the
main criteria used for the review of such units were those
of traditional 'scientific merit', with a later separate
review of policy relevance, this was perceived to have:
threatened the basic assumptions of some research
units. Such units, often with the encouragement of
the DHSS, concentrated on policy-relevant research
that made no pretensions to influence the course of
science. They feared that their work would be sub-
jected to criteria quite different from those prevailing
when they began it [12].
Though some institutional developments from the
Rothschild reforms remained, many aspects of the
reforms, including the transfer of funds from the MRCHanney et al. Health Research Policy and Systems 2010, 8:11
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and the elaborate consultative committee structure,
began to be dismantled from 1978 and did not survive the
1980s. This was partly because of the continuing opposi-
tion to the customer-contractor principle from signifi-
cant parts of the medical research community, and partly
because of the difficulties faced by the Department in act-
ing as an informed customer [11]. Even for policymakers
dealing with issues which were the responsibility of the
central department, the role of customer proved to be
more difficult than anticipated - partly because of the
time required.
NHS R&D programme/Peckham reforms: the NHS as 
consumer of research
As a result of the difficulties in implementing the Roth-
schild reforms, many of the issues related to addressing
the needs of policy costumers were not fully resolved.
There was increasing concern in the UK in the 1980s that
the health research system was still neither properly serv-
ing the needs of the health system itself [64], nor those of
the Department of Health, and, perhaps partly as a result,
that the NHS was not adequately meeting the health
needs of the country. In 1988, an influential Parliamen-
tary review was published by the House of Lords Select
Committee on Science and Technology [13]. Its main rec-
ommendation was that health research should give
greater emphasis to addressing the needs of the NHS,
seen as a research 'customer' in its own right but with an
insufficient voice hitherto [13].
While some reservations were expressed about whether
there would be sufficient organisational capacity and
resources to undertake the wide range of tasks required
[60], and not all the proposals from the House of Lords
Committee were implemented (including the idea of a
National Health Research Authority), many of the key
ideas behind the report were introduced in a major phase
of reform began under the first Director of R&D, Michael
Peckham. The detailed strategy for this phase was set out
in 1991 in Research for Health: A Research and Develop-
ment Strategy for the NHS which claimed that the new
programme 'presents the opportunity of working towards
a coherent national programme of research in collabora-
tion with the MRC, the charities and industry' [17]. To
help achieve this strategy it was intended that over a
period of five years there would be an increase of approx-
ima tely 50% in the budget of the new NHS R&D pro-
gramme so that it reached about 1.5% of the NHS budget.
The main focus of the strategy, which applied in England,
was an attempt to integrate the new NHS R&D pro-
gramme into the management structure of the health
care system. This required a major effort; no other coun-
try had ever attempted such an ambitious approach
[14,65]. A range of issues was addressed, including
attempts to commission research to meet the needs of the
health care system, attempts to encourage the greater
utilisation of research within the health care system, and
various changes in organisation, management and gover-
nance of research. A key role was to be played in this by
the NHS regions within England:
The regions will have a crucial role in the R&D pro-
gramme - helping to shape the overall strategy, setting
their own priorities, directing, commissioning and
managing research and development programmes
and helping to ensure that the results of good
research are used to full effect [17].
However, although using the NHS regional structure
did facilitate attempts to build the R&D process more
closely into the customer organisation, it also made the
R&D system vulnerable to changes in the wider NHS sys-
tem. The regional dimension made a useful contribution
to a range of activities such as agenda-setting and encour-
aging the appreciation and use of research, for example,
as noted above, through the provision of critical appraisal
of research evidence courses [39]. But when the regional
structure of the NHS itself was eventually amended, and
later disbanded, reorganisation of the R&D structure was
also necessary [12].
In aiming to meet the needs of the NHS, another major
element of the new strategy was the creation of a series of
time-limited national NHS R&D programmes [66]. These
covered topics that had been identified as priorities for
the NHS. Most related to specific fields such as the man-
agement of asthma, cardiovascular disease and mental
health, but some were cross-cutting fields, including the
Implementation Methods Programme described below
[50]. A key feature of these programmes was the involve-
ment of a wide range of stakeholders, including patient
representatives, on both Advisory Groups that identified
R&D priorities and on Commissioning Groups that
decided which proposals to fund as part of each pro-
gramme [50].
In addition to the time-limited programmes, in 1993 a
permanent Health Technology Assessment (HTA) pro-
gramme was established following a report that had
emphasised its importance to the NHS [67]. This contin-
ues to the present and has become increasingly successful
in allowing various parts of the health care system to
b e c o m e  m o r e  d i r e c t l y  i n v o l v e d  i n  s e t t i n g  t h e  r e s e a r c h
agenda relating to the assessment of specific treatments,
drugs and devices [55]. Furthermore, it is now 'interna-
tionally acclaimed' [58], and its research is much used by
various policymaking bodies, including those described
above, ie the National Institute for Health and Clinical
Excellence (NICE) and the National Screening Commit-
tee (NSC) [55]. Indeed, NICE was explicitly established in
1999 to serve as a 'receptor' organisation whose work to
inform clinical and commissioning decisions in the NHS
would be directly informed by HTA and other clinicalHanney et al. Health Research Policy and Systems 2010, 8:11
http://www.health-policy-systems.com/content/8/1/11
Page 12 of 23
research [12]. The existence of bodies such as NICE and
the NSC gives authority to some HTAs, thus enhancing
the status of the knowledge production involved in this
type of research, which is important if its impact is to be
sustained [12]. NICE guidance documents have become
increasingly binding on the English NHS. Each one is
informed by a research report specifically commissioned
from the HTA Programme, and NICE also issues advisory
clinical guidelines, which are informed more broadly by
the portfolio of work produced by the HTA and similar
programmes. In general, bodies such as NICE and NSC
act as receptors for a wide body of research conducted in
the English health research system.
Even before the creation of NICE, there were deter-
mined efforts by the health research system to address
the problems of under-utilisation of research within the
National Health Service. These included a research infor-
mation systems strategy which provided funding for the
establishment in 1992 of the path-breaking UK Cochrane
Centre [66] that subsequently inspired the international
Cochrane Collaboration. The strategy also led to the cre-
ation of the NHS Centre for Reviews and Dissemination
at York University, primarily to undertake synthesis of the
findings from clinical research. In addition, in the mid-
1990s, the NHS R&D programme launched the Imple-
mentation Methods Programme which funded pioneer-
ing research into methods to implement research in
clinical practice [68]. This was probably the first research
programme in the world specifically focused on methods
for implementing health research and was a further
important element in the attempt to make the then NHS
R&D system serve the needs of the National Health Ser-
vice [50]. Overall, the information systems strategy has
been one of the most enduring parts of the Peckham
reforms and has had a major international impact. Whilst
progress in terms of greater utilisation of the research has
been more difficult, in the UK it was recognised that in
some areas considerable progress was made on the
uptake of effective, research-based clinical practice, for
example in maternity care [69].
Since at least 1990, consumers and the public have been
involved in different aspects of R&D related to the NHS
[46,47]. In one study published in 2001, 42% of NHS pro-
viders reported that they had involved their patients in
some way in their R&D activities, but there was some
confusion about what this entailed and a lack of aware-
ness about NHS performance indicators for consumer
involvement [46]. An additional element of the NHS R&D
Programme was established in the mid-1990s to make
progress in this field. Originally called 'Consumers in
NHS Research', it continues to this day under the name of
INVOLVE, and aims to ensure, 'that people's involvement
in R&D improves the way that research is prioritised,
commissioned, undertaken and disseminated' [70]. As
with various other issues discussed in this section, some
of the most innovative developments in consumer
involvement came at regional level within the NHS. One
example of an attempt to facilitate the role of the patients
and the public was the use of innovative virtual research
commissioning panels by the R&D Directorate of the for-
mer London Regional Office of the DH [49].
Given the additional resources that were being allo-
cated to the NHS R&D programme it became increas-
ingly important to attempt to demonstrate that wider
impacts or benefits were flowing from the research com-
missioned. Therefore, the Department of Health com-
missioned a stream of work that resulted in the Payback
Framework for categorising and assessing the wider
impacts made by health research [71]. The framework
consists of a multi-dimensional categorisation of benefits
and a logic model to help organise the assessment of the
impact. The Payback Framework was used in guidance
given to directors of DH 'core'-funded units and pro-
grammes about preparing for their DH review: it was
seen as an approach that could be used by the units to
demonstrate the wider impacts that their research was
making on policy and health care within the NHS [12].
In 1996 another programme appeared in official papers
and was formally launched in 2000 as the NHS R&D Ser-
vice Delivery and Organisation Programme [15]. It had a
r e m i t  t h a t ,  a t  l e a s t  a s  v i e w e d  l a t e r ,  s e e m e d  t o  s t r e t c h
broadly to include specific organisational issues of con-
cern to managers as well as key policy issues of concern
to the NHS. There was a potential overlap here with the
direct concerns of the Department of Health, whose cen-
trally commissioned research programme continued to
meet its own research needs throughout the Peckham
reforms. Despite all these positive changes, some of the
difficulties with organising and assessing policy-related
research that had been highlighted by Kogan and Henkel
remained unresolved. In a 2003 analysis that perhaps
downplayed the progress that had been made with initia-
tives such as the HTA programme, a report for The
Health Foundation and the Nuffield Trust identified
many barriers to health services research supporting the
improvement of health care services in the UK [32]. The
report claimed that these barriers included: a lack of
research into prime areas of importance for policymak-
ers, clinicians and managers of clinical services; the fre-
quent inaccessibility of the research that was conducted;
and the fact that the reward structure of the UK's
Research Assessment Exercise (a method used to assess
the performance of university research in the UK with
attendant implications for the distribution of government
funding to universities) did not encourage research rele-
vant to improving the health care service. Some of the
recommendations made in this report echoed the earlier
analysis from Kogan and Henkel [11]. Furthermore, oth-Hanney et al. Health Research Policy and Systems 2010, 8:11
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ers argued that major aspects of the reforms called for by
the House of Lords report, such as an expansion of public
health research, had not been sufficiently implemented
[72].
Another issue that proved to be problematic was the
large amount of continuing NHS R&D funding provided
to meet the NHS costs of hosting research supported by
eligible external funders, such as the MRC and Wellcome
Trust. Attempting to improve the management and coor-
dination of this element of the NHS R&D budget was a
major task throughout this period. Whilst the long battle
to increase transparency and accountability of this money
is described in detail elsewhere [15], it is worth noting
that changes in the NHS itself increasingly impinged on
the R&D system that was trying to meet its needs.
Changes such as the purchaser/provider split meant that
the major research hospitals faced the potential danger of
becoming seen as inefficient health care providers
because of their research and research support costs. To
address these increasingly pressing concerns, the Culyer
review was established in 1994 and the NHS R&D fund-
ing streams were reorganised to protect the research and
teaching hospitals [73]. Various reforms followed but,
even in the early 2000s, concerns were still being
expressed about the level of transparency in using the
£400 million that was spent annually on meeting the NHS
costs of the MRC and charity funded R&D [15].
In the early 2000s, further problems, largely uncon-
nected to the Peckham reforms, began to emerge, includ-
ing those facing medical academics, as described in 2002
in the report from the Academy of Medical Sciences enti-
tled, Clinical Academic Medicine in Jeopardy [74]. This
suggested that increasing service pressures on clinical
academics reduced their time for teaching and research
when other resources were also declining: for example, it
was claimed that the Research Assessment Exercise had
also resulted in falling investment in technical support
staff. As a result of all these pressures, clinical academic
medicine was no longer seen as an attractive career [74].
T h e  n e x t  y e a r  t w o  m o r e  r e p o r t s  b u i l t  o n  t h i s  a n d
reflected the views of a range of stakeholders: the first
was a further report from the Academy of Medical Sci-
ences [75], and the second a report from the Biotechnol-
ogy Innovation and Growth Team [76]. The two reports
identified a series of critical challenges including inade-
quate support for clinical research. In the light of this, the
Research for Patient Benefit Working Party was estab-
lished with the remit to 'bring forward to ministers prac-
tical proposals for implementing the recommendations in
the two reports' [77]. An interim report examined the
components that the two reports had recommended were
necessary to boost clinical science, including the develop-
ment of a clinical research infrastructure embedded in
the NHS, and concluded that government and charitable
funders had made some progress in those areas but it was
by no means sufficient in depth or breadth. The final
report, published in April 2004, endorsed the creation of
the UK Clinical Research Collaboration to encourage the
engagement of a wide range of stakeholders, and stated
that it 'should adopt as its long-term goal establishing the
NHS as the world leader in contributions to clinical
research.' [77]. These developments helped prepare the
way for the next set of reforms.
The 'Best Research for Best Health' Report and the National 
Institute for Health Research: multiple stakeholders 
including patients as consumers of research
In 2005, a further phase of health R&D reform was pro-
posed in the Best Research for Best Health consultative
report [21] and, following consultation, implementation
of its recommendations began in 2006 with the creation
of the National Institute for Health Research (NIHR), led
by the Director of R&D in the Department of Health [9].
These changes re-emphasised the role of research in
addressing the needs of policymakers, managers and
health service providers, but the reforms additionally pre-
sented patients and the general public as the ultimate
consumers or beneficiaries of health research. This was in
line with developing trends elsewhere in health policy.
Several reports had increasingly demanded that health
research should focus on the needs of patients and the
general public [15]. As noted, the Research for Patient
Benefit Working Party had been established and made
recommendations for boosting clinical research in the
NHS. The INVOLVE programme had also been estab-
lished.
Whilst the Best Research for Best Health consultative
document gave considerable emphasis to meeting the
needs of patients, the majority of the eventual reforms
concentrated on the structure and organisation of the
health research system and on ensuring that more clinical
research was to be conducted. The aim of the consulta-
tion was to 'draw out any issues stakeholders may have
had with regard to the strategy, and to inform our final
proposals' [21]. The overall direction of the proposed new
strategy received considerable support during the consul-
tation, but there were inevitably some areas where con-
cerns were raised. These included:
• fears about whether concentration of excellence in
proposed new clinical research centres would drain
the rest of the NHS of talent and research opportuni-
ties;
• concerns that primary care research and non-clini-
cal disciplines might not receive sufficient consider-
ation;
• a view that greater weight should be given to the
resource represented by patients and the public; andHanney et al. Health Research Policy and Systems 2010, 8:11
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• the view that it was important to try to assess the
impacts of the changes in terms of improved health
care outcomes.
The NIHR was established to provide coherence, focus
and status to the different strands of research covered by
NHS R&D and DH funding [9]. In some ways, the pro-
posal for such an Institute reflected the unimplemented
recommendation of the 1988 House of Lords Report in
support of a National Health Research Authority [12,13].
The outstanding feature of Best Research for Best Health
is probably the breadth of the strategy, as highlighted by
Sally Davies, Director of R&D in the DH, in her postscript
to the final strategy document published in 2006 follow-
ing the consultation: 'we want to emphasise that the strat-
egy does not consist of one or two 'big ideas' in isolation'
[9].
Given the wide-ranging nature of the Best Research for
Best Health strategy, it is impossible here to describe all
its elements. Progress on the full range of activities is
described in the NIHR's own reviews of progress [78,79]
and in the regularly updated implementation plans avail-
able on the NIHR web site [80]. Reflecting the govern-
ment's desire for a still more comprehensive approach,
the Cooksey Review of the wider English health research
system began shortly after the Best Research for Best
Health strategy began to be implemented. However, the
Best Research for Best Health strategy has continued
because the implementation of the recommendations
from the Cooksey Review complements that strategy
rather than instituting a different structure. Therefore, in
this section we shall describe the implementation of Best
Research for Best Health to date before going on to
describe the wider reforms that resulted from the Cook-
sey Review and were introduced to run concurrently.
A key feature of the NIHR reforms is that there have
been a series of developments, not all of which were fully
set out at the start of the process in 2005, but all of which
have come under the Best Research for Best Health
umbrella. Therefore, rather than attempt to list all the
developments, the account below highlights some of the
key developments as they relate, in particular, to the
needs of the stakeholder groups described above. Some of
the major themes addressed, therefore, concern how the
strategy attempts to bring various stakeholders together,
how some of the problems facing medical academics are
being tackled, and how the diverse funding streams meet
a variety of needs of the different stakeholders.
Turning to the first of these major themes, the Best
Research for Best Health strategy recognises the impor-
tance of involving a wide range of stakeholders, including
industry and the medical research charities, in identifying
R&D priorities and enhancing the utilisation of research.
Key features of the reforms include building on the
research networks that were beginning to emerge at the
end of the previous phase, and especially on the UK Clin-
ical Research Collaboration created by the DH in 2004 in
partnership with other research funders, industry, regula-
tory bodies, Royal Colleges, patient groups and academia
[81]. One of the striking features of the UK Clinical
Research Collaboration mission set out in 2006 refers to
the importance of meeting the needs of industry by
involving it in agenda-setting for health research within
the NIHR and by providing a suitable location within the
NHS for companies to fund trials of their new drugs and
devices [81].
The UK Clinical Research Network was established to
complement the work of the UK Clinical Research Col-
laboration. This network consists of a managed set of
topic-specific clinical research networks (which at the
time of the 2005 consultation already covered cancer and
mental health), a Primary Care Research Network and
the NIHR Comprehensive Clinical Research Network,
created to provide a world-class infrastructure for clinical
trials in all areas of disease and clinical need within the
NHS [82]. Each network is built up of regionally based
Local Research Networks, and by 2009 there were 25
NIHR Comprehensive Local Research Networks. The
networks are not only intended to remove barriers to the
support of public and charitable funded research by the
NHS and increase the number of people who enter multi-
centre trials, but also 'ensure that the NHS can meet the
health research needs of industry' [9]. The networks
therefore support trials funded by the NIHR itself, and
those funded by 'other partners including the Medical
Research Council, medical charities, such as the Wellome
Trust, and the life sciences industries.' [79]. The various
networks are also designed to ensure that the needs of
industry are met to a greater extent than previously. The
NIHR progress report for 2008/9 also gives examples of
where a Comprehensive Local Research Network helped
fund posts to enable the professionals in local NHS trusts
undertake clinical trials. As noted above, a major reason
behind the creation of the networks was to tackle some of
the problems facing clinical academics.
The feeling that there was a lack of incentives for able
doctors to become medical academics was a major driver
behind the Best Research for Best Health consultative
document. It described disincentives to entry and barri-
ers to progression. In an attempt to address some of these
problems reforms are being introduced by the NIHR,
including: raising the status of researchers through badg-
ing them as 'NIHR faculty' and ensuring their funding is
separate from the NHS's patient care budget; expanding
capacity development programmes for future leaders in
applied health research; and working with UK Clinical
Research Collaboration partners to create additional
training opportunities for clinical academic posts [9]. In
relation to the creation of the NIHR, Shergold and GrantHanney et al. Health Research Policy and Systems 2010, 8:11
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wrote, 'From an historical perspective, the creation of this
outspokenly competitive new body represents the
Department's boldest step yet to exorcise the one time
stigma of its researchers as "second-class scientific citi-
zens"' [10]. An element in achieving this is the appoint-
ment of researchers to a College of NIHR Senior
Investigators. According to the latest progress report:
this prestigious three-to five-year award enables us to
harness the skills and knowledge of the country's
most prominent clinical and applied health research-
ers to tackle the challenges facing the NHS. They are
chosen by rigorous peer review for their outstanding
achievements as the best researchers in their respec-
tive fields. [79]
It remains to be seen how this will develop and, indeed,
the system does depend on researchers identifying them-
selves as the most prominent and applying to join. A fur-
ther crucial departure from the earlier periods is the
recognition that the incentives for applied/health services
researchers, and how their work is assessed, must match
their tasks and research objectives. This was explicitly
recognised both in the NIHR strategy and in the creation
of the independent Health Services Research Network by
the research community itself which is beginning to give
greater recognition to the role of this type of research. In
relation to the 2008 Research Assessment Exercise, the
Department of Health and NIHR successfully helped pro-
mote the idea that the wider impact of research should be
taken into account where relevant. This has helped stim-
ulate further work developing ways of assessing the wider
impact of health research on health policy [83].
To meet a range of objectives and the needs of various
stakeholders, the Best Research for Best Health strategy
proposed to introduce a raft of new funding streams for
projects, programmes, units and centres, in addition to
additional funding for existing programmes such as the
HTA and Service Delivery and Organisation pro-
grammes. Progress was being made on these funding
streams when the Cooksey Review, described in the next
section, highlighted the importance of addressing the two
translational 'gaps' in the production and application of
research and described the critical pathway required to
turn biomedical research developments into health bene-
fits for patients [58]. The framework provided by Cook-
sey provided a structure for the NIHR to develop: both
subsequent NIHR progress reports set out how its fund-
ing schemes fit into, and, in effect, constitute, a major
part of the 'innovation pathway' described in the Cooksey
Review [78].
The success of the NIHR HTA programme was noted
above [55,58], and it illustrates the way in which the
Cooksey Review has enhanced the NIHR. The NIHR
HTA Programme has received increased funding result-
ing from the Best Research for Best Health strategy and
then further increases following the Cooksey Review
[58]. The HTA Programme is not only playing an increas-
ingly important role in informing the decisions of policy
makers and managers in the NHS, but it has also taken
steps to introduce the recommendations of a report on
how to improve patient and public involvement in setting
its research agenda [84].
The NIHR Service Delivery and Organisation R&D
programme provides research for a broad range of poten-
tial users in the health care system. Following the estab-
lishment of the NIHR in 2006, the mission of the Service
Delivery and Organisation programme has shifted to
focus more on producing evidence that improves practice
in relation to the organisation and delivery of health care
and less on the policy-related research that is the respon-
sibility of the DH's Policy Research Programme [85]. As
noted above, this neat distinction is not, however, clear
cut in practice. Compared with the HTA programme
which is largely addressing the needs of clinicians, it is
also generally more challenging for the Service Delivery
and Organisation programme to identify and meet the
needs of managerial stakeholders since they are harder to
identify [32]. Nevertheless, its research too is beginning
to be used by organisations within the health care system
[86] and current initiatives are aimed at enhancing the
capacity of the programme to meet the needs of that sys-
tem [87]. Since its establishment the Service Delivery and
Organisation programme has made considerable efforts
to demonstrate that a wide range of methods should be
seen as appropriate for the type of the research it com-
missions [88]. More recently the NIHR Service Delivery
and Organisation programme has also collaborated with
the Canadian Health Services Research Foundation to
review methods for synthesising qualitative and quantita-
tive, and 'mixed' method research in ways that are useful
for health policymaking and management [89-91].
The HTA programme and the Service Delivery and
Organisation programme are parts of the health research
system that are seen to have a key role in achieving the
increased public participation in health issues (and not
just in research) called for in the 2002 Wanless Report
[92], which considered the long-term resource require-
ments for the NHS in the UK. Wanless set out three sce-
narios related to the degree of public involvement in
health matters. Of the three, the 'fully engaged' scenario
would achieve maximum improvements in health status
at lowest cost. In reviewing progress, Wanless concluded
in 2007 that the population was a long way short of being
'fully engaged'[93]. Wanless referred to the role of the
Service Delivery and Organisation programme and the
Cooksey Review also concluded that an expansion of the
HTA programme would be crucial to the delivery of
Wanless' 'fully engaged' scenario.Hanney et al. Health Research Policy and Systems 2010, 8:11
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The new streams of research funded by the NIHR
include the responsive mode, Research for Patient Benefit
Programme, which 'allows health service professionals
themselves to come up with ideas with the potential to
improve their everyday practice' [79]. A School for Pri-
mary Care Research has been created, and further recent
developments within the NIHR include the launching of
two new programmes. First, a Public Health Research
programme aimed at providing information to enable
public health interventions delivered outside the NHS
and health care settings to be based on sound evidence.
Second, a Health Services Research Programme to fund
studies into better ways of planning and providing health
services, including, for example, studies of cultural and
organisational issues affecting patient safety [79]. These
are areas which had risked being overlooked.
2007 saw the start of one of the major initiatives intro-
duced as part of the NIHR, ie the creation of what are
now 12 Biomedical Research Centres, on which £117 mil-
lion is being spent in 2009/10, and 17 Biomedical
Research Units on which over £20 million a year is being
spent [79]. These University/NHS-based Centres and
Units address several of the issues of concern in relation
to academic medicine and clinical research highlighted
previously. They each support a critical mass of leading
researchers in NHS/university partnerships that are driv-
ing innovation in the prevention, diagnosis and treatment
of ill-health, and are translating advances in biomedical
research into patient benefits. Furthermore, the Centres
and Units provide enhanced support for those wishing to
pursue a career as a medical academic, they have growing
links with industry, and they are fostering new levels of
cooperation between researchers from different disci-
plines, between researchers and the NHS, and also
between researchers and patients. Most recently, some of
these Centres, and in some cases associated Units, have
bee n desi gn a t ed by  t he  Depa rt m e n t  o f  H ea lt h as  A ca-
demic Health Science Centres. The five so designated by
2009 do not receive any additional funding as a result, but
it has already become a much coveted status. However,
even among those who recognise the potential advan-
tages in concentrating considerable resources on the new
Biomedical Research Centres, there is the concern that it
should not be at the expense of less research-intensive
universities and hospitals [94].
Indeed, in the original 2006 strategy document, it was
claimed that the NIHR 'does not aim to be either elitist or
egalitarian' [9] and as well as concentration in the leading
centres some of the developments have tried to encour-
age a wider distribution of some funding to good
researchers throughout the NHS. For example, the Col-
laborations for Leadership in Applied Health Research
and Care (CLAHRCs), have been developed in response
to the Cooksey Review and are aimed at funding partner-
ships between medical schools in various parts of the
country and local NHS organisations to develop innova-
tive ways in which health research can be conducted to
improve the effectiveness of clinical care [78]. This goes
some way to address the fears about a narrow concentra-
tion of research funding within parts of the NHS.
Looking at the current strategy of the NIHR in the con-
text of the earlier phases, it is possible to see it as one of
continuing the integration of the health research system
more closely into the Health Service, and yet at the same
time attempting to provide greater financial indepen-
dence and security for the research system. Writing a
postscript to the 2009 NIHR progress report, Sally
Davies, now Director General of Research and Develop-
ment at the DH states:
When we first launched the NIHR, we...could see the
huge potential for improving, expanding and
strengthening the way that health research is deliv-
ered for patients, the public and the NHS. What we
had to do was create a paradigm shift in the national
research environment and we gave ourselves three
short years in which to achieve the transition. Well,
we have now passed out of transition, and it is true to
say that the NIHR has really taken off [79].
The Cooksey Review and the Office for Strategic 
Coordination of Health Research reforms: including 
industry and other stakeholders
Shortly after implementation of the new National Insti-
tute for Health Research had begun in 2006, the UK Gov-
ernment announced that the Treasury would conduct a
further review of the wider UK medical research field,
taking into account the recent decision to create a single
health research budget amalgamating the research bud-
gets of the MRC and the DH. The resulting Cooksey
Review recommended that a new overarching body be
created to oversee the single research fund: the Office for
Strategic Coordination of Health Research [58].
Whilst the three previous phases of reform were pri-
marily attempts to cater better for specific stakeholders
whose needs were perceived as not being adequately met,
the potential strength of the Cooksey Review, and the
resulting Office for Strategic Coordination of Health
Research, is that the system has been considered as a
whole, including the more basic biomedical research
funded by the MRC and the major medical research char-
ities. The review endorsed the Best Research for Best
Health reforms, and called for structures to encourage
the coordination of the system, including by building on
the efforts of NIHR to structure and formalise the grow-
ing focus on networking between the various stakehold-
ers in the health research system. What was particularly
challenging about the Cooksey Review, perhaps not sur-
prisingly given its Treasury origin, was the extent toHanney et al. Health Research Policy and Systems 2010, 8:11
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which it emphasised the potential contribution of health
research to the UK economy. The opening paragraph of
Cooksey's Review stated:
the Government's vision is of a holistic health R&D
system that will maximise the value of the UK's health
r esear ch base, ensuring t he UK's healt h research is
more closely aligned with wider health objectives,
builds on scientific progress to date, and translates the
results of research into economic benefits [58].
The concerns of industry were prominent in the con-
clusions and recommendations of the Cooksey review
[95]. A key goal, and the one that concludes the foreword
to the report, is that the UK should be, 'an outstanding
location for healthcare companies to develop their busi-
ness' [58]. The Review proposed that government, regula-
tors and industry should create a new partnership 'to
pilot a new drug development "pathway" to create win-
ners for all stakeholders: industry, government, the wider
economy and, most importantly, patients'. One of the key
issues was that the pathway should streamline the pro-
cesses involved in setting up and paying for clinical trials
in the UK.
The underlying theme behind the Cooksey Review was
to ensure that the whole process of knowledge transfer
from 'bench to bedside' worked better. In particular, it
highlighted two translational 'gaps': the need to improve
translation from the laboratory to the creation of new
products and treatments; and then the need for transla-
tion of those new products and approaches into routine
clinical practice [58]. Cooksey made a series of specific
recommendations for how parts of the overall publicly-
funded health research system should collaborate with
industry to tackle these two translation gaps. To address
the first gap, he proposed that the Office for Strategic
Coordination of Health Research (OSCHR) and a new
Translational Medicine Funding Board work with the
health care industries and other stakeholders to develop
proposals for joint private and public investment in new
technologies for medicines' discovery. A Translational
Medicine Board has now been established and its role is
'to work with the OSCHR Partners to develop a coordi-
nated, coherent, fully aligned research strategy in transla-
tional research.' [96]. Specifically to address the second
gap, Cooksey proposed that the NIHR HTA Programme
and NICE should work with industry to identify new
medicines under development that might be suitable for
earlier HTA and earlier NICE guidance decisions [58].
As we have seen, by endorsing the NIHR, the review
helped facilitate the implementation of the Best Research
for Best Health reforms, and in many ways strengthened
them. The Cooksey Report called for better training for
NHS managers and clinical staff to improve their under-
standing of the benefits of research and noted that the
Canadian experience provided an example of how it
might be done [58]. Also in Canada, the review noted,
additional funding to underpin the changes needed at the
time of the establishment of the Canadian Institutes of
Health Research was widely seen as having been of vital
importance to the success of the initiative. One of the
Office of Strategic Coordination of Health Research's key
roles is to make a single submission for health research
funding to the Treasury on behalf of the two government
departments responsible for health research [96]. In its
2007 submission to the Treasury it highlighted the suc-
cess of the NIHR and MRC and outlined an ambitious
programme of coordinated work to enhance translational
research; in October 2007 it secured the largest ever
increase in public funds for UK health research [96]. This
increase is intended to support the areas identified in the
Cooksey report as needing additional funding, including
evaluation and trials to ensure that so called 'basic' sci-
ence is translated into health and economic benefits for
the UK, and public health research. Crucially, the
increase in funding for applied research for 'patient bene-
fit' has this time, unlike in the 1970s, come in the form of
additional funding for health research and not as a switch
in priorities away from basic biomedical science. The
focus on the publicly-funded health research system as a
whole, and its relationship to other stakeholders, followed
by the establishment of the Office of Strategic Coordina-
tion of Health Research, have all been steps towards the
creation of a national health research system.
The Cooksey Review has been seen as 'a masterful
attempt at coherence' [95], and whilst its success is still
not guaranteed, nevertheless, an early assessment of
these reforms in the BMJ in February 2008 was cautiously
optimistic:
So could this prove to be a reorganisation prompted
by a correct diagnosis and followed by a prescription
of the appropriate remedy? The final verdict will
come later . For the moment though that is more or
less how it looks [97]
Lessons for building a health research system
Building any health research system to meet the needs of
diverse stakeholders is complex. Here we present some
general lessons from the analysis about how diverse
needs can best be met, and at each stage make some
observations about how far the reforms in English system
have met stakeholder needs. We also discuss recommen-
dations for both the English system and more generally.
1. Facilitating overall and ongoing coordination
Kogan and Henkel's analysis, in particular, highlighted
that the many elements in a system of health research
create tensions between stakeholders as different people
represent different interests and fulfil different roles, with
accompanying differences in values [12]. As we haveHanney et al. Health Research Policy and Systems 2010, 8:11
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stated, the key stakeholders include health care policy-
makers, health care providers, patients, industry, and, of
course, researchers themselves. The needs of these five
groups are summarised in Figure 1. The first lesson,
therefore, is the importance of addressing as coherently
as possible the diverse needs of the institutions and actors
that interact in any health research system and recognis-
ing that a degree of coordination will be necessary. But it
goes further than this: there is a need to develop appro-
priate structures (such as the new NHS/university collab-
orations being developed by NIHR), build cultures, and
fully and effectively use developing technologies such as
systematic reviews. It is important to note that to meet
the needs of all the stakeholders it is likely that a full
range of research should be undertaken, including Mode
1 and Mode 2 research as described in the Introduction.
In promoting this coordination, research managers can
play an important role by strengthening the interfaces
between various stakeholder groups. This role is often
overlooked and consequently under-resourced [12]. The
main things that research managers need from the health
research system are recognition of their role (in all its
complexity) and adequate resourcing of research man-
agement tasks. In order to be able undertake their roles,
research managers need a range of capacities [11,12],
including being able to: establish and manage some of the
research interface mechanisms described below; commu-
nicate and broker different R&D needs and findings; and
identify and resolve gaps and conflicts between groups,
and synthesise research perspectives.
More generally, it is important to realise that in com-
plex systems there are always new challenges arising and
new perspectives developing both as a result of continu-
ing consultation and as a result of new research into vari-
ous aspects of the system. This puts a premium on the
system being flexible enough to adapt to developing
thinking, whilst being sufficiently robust to maintain the
key elements. In organising and running the health
research system, it is appropriate to keep in mind the
more general lesson proposed by Alan Irwin about the
importance for the relationship between science and
society of 'the development of an open and critical dis-
cussion between researchers, policy-makers and citizens'
[5].
Looking specifically at the system in England, through-
out the last four decades we have seen some continuities
in terms of developments that have lasted, for example,
the idea of having applied research units focused on spe-
cific needs of the health care system. We have also seen
other examples of reversals. But, and particularly over the
last two decades, many of the initial advances have con-
solidated as those running the health research system,
often working closely with those running the health care
system, have increasingly attempted to analyse and
reform the system as a whole. Examples of where this has
worked well include the HTA programme established as
early as 1993 to undertake research explicitly to meet the
needs of the NHS. Its role and importance increased with
the establishment in 1999 of NICE which has acted as a
k e y  ' r e c e p t o r '  b o d y  f o r  m u c h  o f  i t s  r e s e a r c h .  I t s  r o l e
expanded subsequently and finally its role has expanded
even more within the 'innovation pathway' set out by
Cooksey. The key elements of the information systems
strategy established in the 1990s, including the UK
Cochrane Centre and the Centre for Reviews and Dis-
s e m i n a t i o n  a t  t h e  U n i v e r s i t y  o f  Y o r k ,  c o n t i n u e  t o  b e
funded as core elements of the NIHR and have been
hugely influential, both in the UK and elsewhere.
The NIHR, created in 2006, has gone further than pre-
vious arrangements in explicitly incorporating the needs
of stakeholders such as industry, and addressing the
growing problems that were facing medical academics. In
general these developments seem to have been organised
in a way that has not been obviously at the expense of
existing key stakeholders. Patients and the public con-
tinue to be regarded as a key stakeholder group, and the
initial steps taken in the 1990s, such as the introduction
of patient representatives onto commissioning panels and
the later creation of INVOLVE, have been built on,
although to date it is difficult to assess the impact of prog-
ress on some of these issues [45].
Some of the initiatives in the 1990s, especially the cre-
ation of Regional R&D structures, were largely discontin-
ued because of changes in the wider NHS. But
subsequently the creation of the Local Clinical Research
Networks, operating at a regional level, indicates that
developments at this level are still seen as playing an
important role in the success of the overall system. These
developments should be less vulnerable to changes in
specific NHS healthcare structures.
Probably the most striking feature of the reforms intro-
duced since 2006 through the NIHR has been the attempt
to integrate a range of initiatives into a NHS/DH system
that builds on existing strengths, and operates with an
effective level of coordination to meet the needs of vari-
ous stakeholders. More recently, with the Cooksey
Review, there have been largely successful attempts to
develop a coordinated system for the whole of portfolio of
publicly-funded health research and to do so in a way
which also engages in effective liaison with stakeholders
such as industry and the medical research charities.
Three key features stand out here. First, Mode 1 and
Mode 2 research are both supported and integrated into
an overall system in the 'innovation pathway'. Second, the
drive towards creating structures to foster effective trans-
lational research provides an overall rationale for many
recent developments. Third, the increased public funding
for health research during the lifetime of the NIHR hasHanney et al. Health Research Policy and Systems 2010, 8:11
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created the circumstances in which most stakeholders in
the health research system have been in some way 'win-
ners'. As discussed later, how sustainable this will be
remains to be seen.
2. Need for interface mechanisms
A  s e c o n d  l e s s o n  i s  t h a t  i t  i s  e s s e n t i a l  t o  d e v e l o p ,  o r
strengthen, mechanisms at the interfaces between the
health research system and different groups to address
their needs, and to enhance understanding, communica-
tion and the use of research. Evidence about research
management highlights the need to develop effective
interfaces between researchers and policymakers, profes-
sionals and patients [4,11,16]. What is absolutely key here
is that, unless there is acknowledgement of the specific
needs and interests of different groups, and an analysis of
the required interface or boundary tasks to meet these
needs, any strategy risks under-achieving. Kogan and
Henkel highlighted the many issues that arise at the
boundaries between a research system and the wider
society when the research system moves beyond concen-
trating on purely traditional academic concerns [12]. This
approach was built on in the Payback Framework devel-
oped to assess the wider impacts of health research and in
the 'interfaces and receptor' model [16,40]. A series of key
interface or boundary tasks and activities can be identi-
fied for a health research system that is attempting to
meet the needs of the health care system and the econ-
omy. They include:
• research problem and needs identification, and
agenda setting (priorities);
• research commissioning in line with the identified
priorities;
• reviewing and synthesising research;
• communicating findings to the health care system,
patients and the wider society;
• facilitation of research absorption and utilisation in
the health care system; and
• performance assessment and incentives for
researchers working on applied research issues.
The first column of Table 2 illustrates the generic tasks
at the interfaces, as discussed above. The second column
illustrates some of the mechanisms that now exist in the
English health research system to undertake these 'inter-
face' tasks. It has been possible to develop a system that
addresses many of the interface issues and, at least to
some extent, allay the concerns listed above that were
raised in the original consultation on Best Research for
Best Health. But despite recent progress the third column
shows there are still some areas in the English system that
might potentially require more attention.
Some of these are discussed below and a fuller list of
points is summarised in Table 2:
A. In terms of problem identification and agenda set-
ting, considerable progress has been made in allowing a
range of stakeholders to contribute to identification of
research topics, but a lesson from the Rothschild reforms
is that it can require a major time commitment from poli-
cymakers and they may not always be willing to engage
sufficiently with researchers. It is not entirely clear how
much scope there is for collaborative development of
research agendas on the major, and system-wide, policy
areas, especially in some of the non-medical or techno-
logical areas (for example, issues to do with the educa-
tion, careers and working conditions of health
professionals) that have generally received less attention.
Furthermore, the emphasis on translational research has
also highlighted the need for greater collaboration
between researchers from different backgrounds, for
example, basic and clinical researchers. Attempting to get
researchers from different backgrounds to work together
on developing agendas is one of the issues being
addressed by some of the recent developments in the
NIHR, including Biomedical Research Centres and Units.
B .  I n  r e l a t i o n  t o  r e s e a r c h  c o m m i s s i o n i n g  t h e r e  h a v e
been various successful initiatives to involve a wider
range of stakeholders (for example, in the HTA pro-
gramme), but despite widely available and regularly
updated guidance from INVOLVE it is not yet clear that
ways have been found to address all the difficulties that
face patients and the public seeking to play a full role in
research commissioning groups [45].
C. It is not clear how potential conflicts will be resolved
between the pressures to speed up processes in transla-
tional research such as the production of HTA reports for
NICE, and at the same time allow researchers to control
the research process to ensure high quality.
D. The health research system in Canada has in some
ways gone further than the English system in demonstrat-
ing the scope for developing both research 'brokerage'
roles to link with users [98] and training programmes to
develop the absorptive capacity for research in health
care organisations and among other stakeholders.
E. Whilst the Biomedical Research Centres and Units,
and now the Academic Health Science Centres, are
promising innovations [94] and there is a wider set of
funding streams than originally proposed in Best
Research for Best Health, it is not entirely clear how far
there will be sufficient resources to allow research to be
undertaken throughout the NHS in a way that is likely to
increase its absorptive capacity and hence its eventual use
of research. Furthermore, population health literacy pro-
grammes are likely to need further development.
F. In the 2008 Research Assessment Exercise, pressure
from the DH/NHS research system, and subsequently
from the NIHR, helped address many of the previous dif-Hanney et al. Health Research Policy and Systems 2010, 8:11
http://www.health-policy-systems.com/content/8/1/11
Page 20 of 23
ficulties that had existed at the interface between the
higher education research system (with its norms of
assessing research according traditional academic crite-
ria) and researchers working in, and for, the health care
system. Furthermore, there is now growing recognition
within new NIHR institutions (such as the Biomedical
Research Centres and the Collaborations for Leadership
in Applied Health Research and Care) of the value of the
contributions from different disciplines. Nevertheless,
there is probably still a need for mechanisms to ensure
Table 2: Illustrative examples of interfaces/boundary tasks and mechanisms
Tasks & activities at the interfaces/
boundaries between stakeholders
Examples of interface mechanisms in 
English Department of Health's R&D 
system
Areas that may require more attention
Agenda setting/research problem 
definition: 
Research funders scoping research needs 
and priorities, negotiation/consultation 
with the various stakeholders
The role of the Biomedical Research 
Centres in bringing many interests 
together; advisory groups e.g. HTA, for 
consumer involvement; NICE; various UK 
health research collaborations and clinical 
research networks that involve many 
stakeholders including industry.
Capacity to undertake collaborative 
comprehensive/systems needs 
assessment, especially for policy research 
in some non medical areas (eg workforce 
issues) where there has been less focus.
Research commissioning: 
Engaging stakeholders in research 
specification & selection of researchers
Diverse commissioning panels for the 
wide range of NIHR programmes, 
including HTA, SDO programmes.
Development of role of different actors 
(especially patients/public) and the need 
for innovative methods to involve them.
Research processes: 
Researcher control of methods but liaison 
between researchers & users during 
projects & collaboratively undertaking 
research
DH Research Liaison Officers; clinical 
research networks help to ensure research 
capacity is developed.
Researchers' ability to control methods 
when demands are made for speeding up 
of processes
Reviewing & synthesising research HTA & SDO programmes; funding for UK 
Cochrane Centre and Centre for Reviews 
and Dissemination (CRD); DH Policy 
Research Programme projects.
Agreed upon methods and capacity for 
reviewing organisational and policy 
research; building on the SDO/Canadian 
initiative;
Research communication: 
Formatting research for different users; 
research brokerage; research networks
CRD; DH Research Liaison Officers; Cabinet 
Office Policy Hub; topic-specific research 
networks; integrating research 
information systems & databases.
Expanding research brokerage to link user 
groups at the systems level; developing 
systems-level media and communication 
strategy
Facilitation of research absorption & 
utilisation: 
Building capacity to receive and use 
research for policy, practice, and informed 
health decision-making
NICE; National Screening Committee; 
clinical research networks; NIHR 
Biomedical Research Centres and Units 
and Collaborations for Leadership in 
Applied Health Research and Care will lead 
adoption of research into clinical practice
Strengthening capacity, eg of receptor 
bodies for SDO and policy research; further 
developing absorptive capacity widely 
through NHS - geographic spread and the 
full range of staff; further improving 
population health literacy.
Research performance assessment NIHR successfully argued for wider 
impacts of health research on policy and 
practice to be included in the Research 
Assessment Exercise as it is in the review of 
DH research units
Ensuring NHS performance measures 
reflect research contributions.
Research incentives: 
Appropriate for different types of research
Researchers (ie 'Faculty') becoming part of 
NIHR to attract clinical researchers; Senior 
Investigators important.
Further development of ways to recognise 
health services and policy research 
contribution to healthcare and the wider 
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that the work of health researchers is assessed ex post on
the basis on which it was commissioned and funded
rather than according to other criteria.
In summary, despite the considerable progress
described above, and in Table 2, it also clear there are still
some problems at the interfaces, and a need for resources
to develop mechanisms to address them.
3. Funding implications and accountability
It is an obvious, but vital, lesson that additional money is
very important in being able to undertake additional
applied research whilst maintaining the funding for basic
science. At one level this is obvious, but the comparison
offered here between the Rothschild reforms and the
NIHR/Cooksey reforms provides further empirical evi-
dence to support the notion, noted by Cooksey in relation
to the reforms in Canada [58], that reforms will go more
smoothly when there are additional resources rather than
a redistribution. Furthermore, in any system transpar-
ency and accountability mechanisms are very important
as are appropriate incentives.
In the English health research system as now created
following the various reforms, it remains to be seen
whether the current arrangements will be able to cope
with the likely reduction in UK Government research
funding in the future.
Conclusions
Substantial claims are being made that the latest NIHR
strategy has largely become a reality. Our combined
stakeholder and historical analysis has enabled us to
examine how far the current system has built on previous
initiatives, and how far it addresses previously unresolved
concerns articulated by the principal stakeholders in the
health research system. The analysis indicates that the
latest strategy for publicly funded health research in Eng-
land sensibly both builds on recent progress and tackles
acknowledged weaknesses. The strategy goes a consider-
able way to meeting the needs of medical academics,
patients and industry through a system that should
improve and simultaneously expand translational, clinical
and applied health research, and increase the extent to
which research is then used in the health care system. It is
doing this in various ways, including building research
networks and infrastructural support, increasing effi-
ciency in recruiting research subjects, and developing
new funding streams and more institutional capacity for
conducting the necessary research.
Analyses of previous reforms demonstrate the com-
plexity of meeting and reconciling the needs of the ever-
increasing range of stakeholders. Attempts to get
researchers and potential research users to work together
face recurring difficulties. The task of co-ordinating the
whole enterprise must be given sufficient recognition and
resourcing, as must the necessary organisational arrange-
ments and interface mechanisms, which greatly vary with
different types of research. Considerable progress is being
made in addressing these issues by the new NIHR and
also, following the Cooksey Review, by the strategy for
the whole health research system in England. But, inevi-
tably, some issues will need further attention.
The new strategy has also been remarkably successful
in increasing the funding for health research in England.
But, and especially in the context of the budget con-
straints in the UK public sector from 2010 onwards, it is
increasingly important that the health R&D system is
seen to be undertaking and producing research that
meets the needs of the many stakeholders now involved.
This will be necessary to ensure that the health research
system retains their continuing commitment. Research-
ers as core stakeholders in a research system often
emphasise the focus on research utilisation should be bal-
anced with an understanding of the creative and often
unpredictable nature of research and its impact. The
additional funding has thus far been very important in
sustaining the support of the academic community who
believe that beyond the instrumental value of addressing
specific stakeholders' needs, research has inherent value
as a valid and reliable way to advance knowledge in
human experience.
T h e  p r o g r e s s  s o  f a r  a c h i e v e d  b y  t h e  r e f o r m s  t o  t h e
health research system in England suggests that the needs
of a wide range of stakeholders can be met. We therefore
conclude that this approach could usefully inform
attempts elsewhere to develop health research systems
that are similarly responsive.
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